1995
DOI: 10.1021/jf00056a035
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of .beta.-Ionone in the Chemoprevention of Rat Mammary Carcinogenesis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
25
0
4

Year Published

1999
1999
2021
2021

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 44 publications
(29 citation statements)
references
References 28 publications
0
25
0
4
Order By: Relevance
“…Tumor incidence was decreased in a dose-dependent manner during the 24-week study. Yu et al 16 reported that the potency of b-ionone in suppressing HMGR activity exceeds these of other monoterpenes. In parallel trials, the efficacy of b-ionone was greater than that of equal intakes D-linmonene and geraniol in mammary cancer chemoprevention.…”
Section: Expression Of Apoptosis Bcl-2 and Bax In Mammary Cancer Tismentioning
confidence: 99%
See 1 more Smart Citation
“…Tumor incidence was decreased in a dose-dependent manner during the 24-week study. Yu et al 16 reported that the potency of b-ionone in suppressing HMGR activity exceeds these of other monoterpenes. In parallel trials, the efficacy of b-ionone was greater than that of equal intakes D-linmonene and geraniol in mammary cancer chemoprevention.…”
Section: Expression Of Apoptosis Bcl-2 and Bax In Mammary Cancer Tismentioning
confidence: 99%
“…10,12 In addition, b-ionone could also affect metastasis in B16 and SGC-7901 cancer cell lines. 11,12,15 Dietary studies reveal the chemopreventive 16 and antitumor 17 activities of b-ionone.This study confirms and extends observations of the chemopreventive impact of, and actions triggered, by dietary b-ionone during DMBA-initiated mammary carcinogenesis in Sprague-Dawley rats. …”
mentioning
confidence: 99%
“…The new data presented here showing that treatment with GO reduced the total number of ACF in this region, as well as the number of ACF ≥4 crypts, lesions with a more advanced and aggressive phenotype (33), reinforce the idea that acyclic isoprenoids may be a chemopreventive agent against colon carcinogenesis. To the best of our knowledge, in vivo studies of chemoprevention with GO have only been conducted in liver, breast and pancreas carcinogenesis models, with inhibition of hepatic PNLs (9,10) and mammary (11,34) and pancreatic (12) neoplastic lesions, respectively. Recently, βI was reported to have chemopreventive activity in liver (8,10), breast (3,11) and colon (14) carcinogenesis.…”
Section: Discussionmentioning
confidence: 99%
“…GO inhibited the growth of mammary and pancreatic neoplasms in rats and hamsters, respectively (11,12), and proved to be an effective adjuvant in the treatment with 5-fluorouracil of human colorectal cancer cells transplanted in Swiss nu/ nu mice (13). βI also reduced the incidence of mammary neoplasms in rats (3,11) and, more recently, it was shown to inhibit the number and size of preneoplastic lesions (PNLs) in the colon when administered in the diet to F344 rats (14). Similarly, other isoprenoids such as perillyl alcohol (15), squalene (16), geranylgeraniol, farnesol, and lanosterol (17,18) also showed chemopreventive activity in a colon carcinogenesis model induced by azoxymethane.…”
mentioning
confidence: 96%
See 1 more Smart Citation